June 17, 2010

CanBas Co., Ltd.
Takeda Pharmaceutical Company Limited

CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer

Numazu and Osaka, Japan – June 17, 2010 --- CanBas Co., Ltd. (Numazu, Shizuoka, “CanBas”) and Takeda Pharmaceutical Company Limited (Osaka, “Takeda”) today announced that both parties terminated the worldwide collaboration for CBP501 and its backup compound, both of which were discovered by CanBas.

Under the terms of collaboration agreement signed on March 30, 2007, CanBas and Takeda’s wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, MA) had jointly initiated Phase II trials of CBP501 in patients with non-small cell lung cancer and malignant pleural mesothelioma.
Takeda and CanBas had found the difference of viewpoints on each part for future development plan of CBP501, and both parties discussed the matter and mutually agreed to terminate the original agreement, effective June 15, 2010, following a reprioritization of the Takeda’s oncology pipeline for the purpose of efficient investment in selected projects.

CBP501 efficacy and safety data obtained to date does not preclude future development in the indications under study in Phase II trials.

CanBas will continue the CBP501 clinical trials as scheduled with the aim of achieving the earliest possible launch, based on the data obtained to date.

Upon termination of the agreement, CanBas will receive a one-time JPY 750 million payment consisting of the accrued development expenses payable and compensation for the termination, and Takeda will be released from all future financial obligations.

# # #

About CanBas

CanBas was spun off of the research of three scientists from the Nagoya City Medical School and Fujita Health Medical School. These scientists founded CanBas as a drug development biotech with the help of angels and venture capitalists in 2000. Additional information is available through its corporate website, .

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

# # #

Contacts:

CanBas Co., Ltd.
Administration Department
Telephone: 81-55-954-3666

Takeda Pharmaceutical Company Limited
Corporate Communications Dept. (PR/IR)
Telephone: 81-3-3278-2037